CTI BioPharma Corp. (CTIC) Social Stream

Featured Post From StockTwits About CTIC

$CTIC Key Statements from this link:
https://www.fool.com/earnings/call-transcripts/2021/08/07/cti-biopharma-ctic-q2-2021-earnings-call-transcrip/

The FDA's acceptance with priority review of our NDA submission for the use of pacritinib in myelofibrosis patients with thrombocytopenia underscores the unmet medical need in this area. Our PDUFA target action date is November 30, 2021.

To address this need, our team has been working diligently on pre-commercialization activities, including market access, distributions, supply chain, disease education, and field force deployment. We are eager to commercially launch pacritinib immediately upon approval from the FDA.

And given our applications prior to review status, we are prepared to launch on the PDUFA date or earlier. In preparation for an early launch, we have completed the hiring of our field force leadership team and started to recruit our key account managers, who will be our sales force.